Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA.
Int J Tuberc Lung Dis. 2012 Jul;16(7):891-6. doi: 10.5588/ijtld.11.0795. Epub 2012 Apr 9.
Alcohol use increases the risk of multidrug-resistant tuberculosis (MDR-TB) and poses challenges for successful MDR-TB treatment, including the potential for additional adverse events.
To investigate the association between alcohol consumption during MDR-TB treatment and adverse events and treatment outcomes in a cohort of patients in Tomsk, Russia.
From 2000 to 2004, retrospective data were collected on 407 MDR-TB patients in Tomsk. Factors associated with treatment outcomes were assessed using logistic regression.
Of the 407 patients, 253 (62.2%) consumed alcohol during treatment ('drinkers'), and 367 (90.2%) had at least one documented adverse advent. No significant differences were noted in frequency of adverse events in drinkers vs. non-drinkers. Drinkers had less favourable treatment outcomes (OR 0.28, 95%CI 0.18-0.45). Among drinkers, favourable treatment outcome was associated with adherence to at least 80% of prescribed doses (OR 2.89, 95%CI 1.30-6.43) and the occurrence of an adverse event requiring treatment interruption (OR 2.49, 95%CI 1.11-5.59).
Alcohol use did not appear to increase the risk of adverse events during MDR-TB treatment; however, alcohol consumption was associated with poor outcome. Our findings suggest that individuals who drink alcohol should receive aggressive attention to optimise treatment adherence and manage adverse events.
饮酒会增加耐多药结核病（MDR-TB）的风险，并对 MDR-TB 治疗的成功带来挑战，包括潜在的更多不良事件。
在俄罗斯托木斯克的一组患者中，调查 MDR-TB 治疗期间饮酒与不良事件和治疗结局之间的关系。
2000 年至 2004 年，回顾性收集了托木斯克 407 例 MDR-TB 患者的数据。使用逻辑回归评估与治疗结局相关的因素。
在 407 例患者中，253 例（62.2%）在治疗期间饮酒（“饮酒者”），367 例（90.2%）至少有一次记录的不良事件。饮酒者与非饮酒者的不良事件发生率无显著差异。饮酒者的治疗结局较差（OR 0.28，95%CI 0.18-0.45）。在饮酒者中，治疗结局良好与至少 80%的规定剂量的依从性（OR 2.89，95%CI 1.30-6.43）和需要中断治疗的不良事件的发生（OR 2.49，95%CI 1.11-5.59）相关。
饮酒似乎不会增加 MDR-TB 治疗期间不良事件的风险；然而，饮酒与不良结局相关。我们的研究结果表明，饮酒者应得到积极关注，以优化治疗依从性并管理不良事件。
